We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific Strong on Growth Goals and Future Launches
Read MoreHide Full Article
At an investment community meeting in New York City of late, Boston Scientific Corporation (BSX - Free Report) presented a review of its long-term growth strategy and offered plans for product pipeline and strategic investments. According to the company, this is aimed at improving its clinical and economic outcomes, sustaining category leadership in served markets and expanding into high-growth, adjacent markets.
Overall, this long-range strategy is expected to help the company deliver a strong financial performance across its MedSurg, Rhythm and Neuro, and Cardiovascular segments.
An Outline of the Strategy
The plan focuses on spaces like category leadership strategy, product diversification into faster-growth markets and expansion of portfolio and capabilities across geographies. In this regard, Boston Scientific noted that last year, it invested approximately $1 billion in R&D and also announced 10 strategic acquisitions in support of its category leadership scheme.
Based on these investments, the company expects to introduce approximately 75 products by 2022. Going by the company’s report, “many of these innovations are focused on adjacencies that are expected to expand our leadership in $22 billion in high growth markets by 2022.” According to the company, by 2022, these product launches will help 80% of its sales to reach high and moderate -growth markets.
Per a Mass Device report, “The company is looking to shift about 35% of its sales to high-growth markets, compared with about 25% today, and to cut low-margin sales to roughly 20%, versus about 30% today.”
In terms of geographic growth, Boston Scientific is working on widening its footprint in the emerging markets along with increasing patient access to care and supporting steady broad-based progress through physician training capabilities, channel explosion and local partnerships.
Financial Goals
During the period from 2019 to 2022, the company is targeting double-digit adjusted earnings per share via the company’s ongoing adjusted operating margin improvement initiatives, which is projected to drive 50-100 basis points of expansion annually. The company has also targeted an organic revenue CAGR of 6-9% during the 2020-2022 time frame.
Share Price Performance
Over the past year, shares of Boston Scientific have outperformed the industry it belongs to. The stock has rallied 27.3% compared with 6.9% rise of the industry.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Cooper Companies’ long-term earnings growth rate is estimated at 10.8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Boston Scientific Strong on Growth Goals and Future Launches
At an investment community meeting in New York City of late, Boston Scientific Corporation (BSX - Free Report) presented a review of its long-term growth strategy and offered plans for product pipeline and strategic investments. According to the company, this is aimed at improving its clinical and economic outcomes, sustaining category leadership in served markets and expanding into high-growth, adjacent markets.
Overall, this long-range strategy is expected to help the company deliver a strong financial performance across its MedSurg, Rhythm and Neuro, and Cardiovascular segments.
An Outline of the Strategy
The plan focuses on spaces like category leadership strategy, product diversification into faster-growth markets and expansion of portfolio and capabilities across geographies. In this regard, Boston Scientific noted that last year, it invested approximately $1 billion in R&D and also announced 10 strategic acquisitions in support of its category leadership scheme.
Based on these investments, the company expects to introduce approximately 75 products by 2022. Going by the company’s report, “many of these innovations are focused on adjacencies that are expected to expand our leadership in $22 billion in high growth markets by 2022.” According to the company, by 2022, these product launches will help 80% of its sales to reach high and moderate -growth markets.
Per a Mass Device report, “The company is looking to shift about 35% of its sales to high-growth markets, compared with about 25% today, and to cut low-margin sales to roughly 20%, versus about 30% today.”
In terms of geographic growth, Boston Scientific is working on widening its footprint in the emerging markets along with increasing patient access to care and supporting steady broad-based progress through physician training capabilities, channel explosion and local partnerships.
Financial Goals
During the period from 2019 to 2022, the company is targeting double-digit adjusted earnings per share via the company’s ongoing adjusted operating margin improvement initiatives, which is projected to drive 50-100 basis points of expansion annually. The company has also targeted an organic revenue CAGR of 6-9% during the 2020-2022 time frame.
Share Price Performance
Over the past year, shares of Boston Scientific have outperformed the industry it belongs to. The stock has rallied 27.3% compared with 6.9% rise of the industry.
Zacks Rank & Key Picks
Boston Scientific carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Cerner Corporation , Penumbra (PEN - Free Report) and The Cooper Companies (COO - Free Report) , each with a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Cooper Companies’ long-term earnings growth rate is estimated at 10.8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>